Spyglass Pharma (SGP) Stock Price, News & Analysis

Company Overview

SpyGlass Pharma, Inc. is an ophthalmic pharmaceutical company developing sustained drug-delivery technologies for the treatment of eye diseases. The company’s platform is designed to provide continuous delivery of medication within the eye, with the goal of reducing reliance on daily topical eye drops and improving treatment adherence.

SpyGlass Pharma’s lead product candidate is an investigational drug-delivery system intended to treat glaucoma and ocular hypertension. The implant is designed to be placed in the eye during cataract surgery and release a therapeutic agent over an extended period, potentially providing longer-term control of elevated intraocular pressure.

The company is advancing its technology through clinical development and regulatory processes in the United States. SpyGlass Pharma is based in California and focuses primarily on ophthalmic conditions, although its product candidates remain investigational and are subject to clinical and regulatory review.

Key Stats

• Today's Range: $29.41 to $30.99
• 50-Day Range: $23.69 to $29.33
• 52-Week Range: $17.06 to $32.44
• Volume: 40,975 shs
• Average Volume: 106,747 shs
• Market Capitalization: $1.03 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.00
• Consensus Rating: Moderate Buy

Spyglass Pharma Stock Analysis - MarketRank™

Spyglass Pharma scored higher than 56% of companies evaluated by MarketBeat, and ranked 461st out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Spyglass Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Spyglass Pharma has a consensus price target of $44.00, representing about 43.7% upside from its current price of $30.63.

Amount of Analyst Coverage

Spyglass Pharma has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Spyglass Pharma are expected to decrease in the coming year, from ($2.55) to ($2.83) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Spyglass Pharma is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Spyglass Pharma is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.66% of the float of Spyglass Pharma has been sold short.

Short Interest Ratio / Days to Cover

Spyglass Pharma has a short interest ratio ("days to cover") of 15.65, which indicates bearish sentiment.

Change versus previous month

Short interest in Spyglass Pharma has recently decreased by 2.34%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Spyglass Pharma does not currently pay a dividend.

Dividend Growth

Spyglass Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.68

News Sentiment

Spyglass Pharma has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Spyglass Pharma this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for SGP on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Spyglass Pharma insiders have not sold or bought any company stock.

Percentage Held by Institutions

Spyglass Pharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SGP
• CIK: 1778922
• Web: www.spyglasspharma.com
• Phone: (949) 284-6904
• Fax: N/A
• Employees: 65
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Spyglass Pharma: $44.00
• High Price Target: $62.00
• Low Price Target: $37.00
• Potential Upside/Downside: +43.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.87 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -62.40%
• Return on Assets: -24.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 25.06
• Quick Ratio: 25.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,430,000
• Free Float: N/A
• Market Cap: $1.02 billion
• Optionable: N/A
• Beta: N/A